Last reviewed · How we verify
CD20-positive follicular lymphoma
Approved treatments
- Gazyva · Roche
Gazyva binds to the CD20 antigen on B-lymphocytes, triggering their destruction. - Gazyvaro · Incyte Corporation
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- CD20-positive follicular lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- CD20-positive follicular lymphoma treatment landscape brief
- CD20-positive follicular lymphoma treatment updates RSS
Frequently asked questions about CD20-positive follicular lymphoma
What drugs treat CD20-positive follicular lymphoma?
Tracked treatments include Gazyva, Gazyvaro.
What is the treatment for CD20-positive follicular lymphoma?
Standard treatment for CD20-positive follicular lymphoma includes Gazyva, Gazyvaro. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: CD20-positive follicular lymphoma patent cliff · CD20-positive follicular lymphoma CI report
- Treatment: Gazyva · Roche
- Treatment: Gazyvaro · Incyte Corporation
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing